Rituximab

Abstract

Rituximab has recently been shown to be effective for chronic ITP. Though it is still in off-label use, current guidelines recommend rituximab as second- or third-line therapy. At the same time, its toxicity must be taken into account, and all the appropriate precautions should be performed before its use.